Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: APN008
MIFTS: 68

Apnea, Obstructive Sleep

Categories: Mental diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Apnea, Obstructive Sleep

About this section

MalaCards integrated aliases for Apnea, Obstructive Sleep:

Name: Apnea, Obstructive Sleep 58
Obstructive Sleep Apnea Syndrome 58 12 26 30 6 15
Obstructive Sleep Apnea 12 77 26 15 64 17
Sleep Apnea, Obstructive 26 45 74
Upper Airway Resistance Sleep Apnea Syndrome 26 74
Sleep Apnea/hypopnea Syndrome 58 26
Osas 58 26
Sahs 58 26
Osa 58 26
Sleep Apnea/hypopnea Syndrome; Sahs; Osahs 58
Obstructive Sleep Apnea Syndrome; Osas 58
Sleep Apnea Syndrome, Obstructive 26
Sleep Apnea Hypopnea Syndrome 26
Sleep Apnea Obstructive 56
Sleep Apnea Syndromes 74
Apnea, Obstructive 26
Obstructive Apnea 26
Osahs 26

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
apnea, obstructive sleep:
Inheritance autosomal dominant inheritance


Classifications:

MalaCards categories:
Anatomical: Mental diseases Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0050848
OMIM 58 107650
ICD9CM 36 327.23
MeSH 45 D020181
SNOMED-CT 69 78275009
ICD10 34 G47.33
MedGen 43 C0520679
Sources

Summaries for Apnea, Obstructive Sleep

About this section
PubMed Health : 64 About obstructive sleep apnea: We all know what it is like to feel tired after a sleepless night because of things like noise, worries or stress. But what if you do actually get enough sleep and still feel absolutely beat the next morning? This is normal for many people with obstructive sleep apnea (OSA): They do not get enough air while they are sleeping (but do not usually notice this), have breathing pauses, and feel very sleepy during the day. In the long term, this increases their risk of developing other illnesses and can have a huge effect on their quality of life.

MalaCards based summary : Apnea, Obstructive Sleep, also known as obstructive sleep apnea syndrome, is related to kawasaki disease and gestational diabetes, and has symptoms including seizures, tremor and dyspnea. An important gene associated with Apnea, Obstructive Sleep is LEP (Leptin), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and Selenium Micronutrient Network. The drugs Guanfacine and Hydrochlorothiazide have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are focal impaired awareness seizure and obstructive sleep apnea

Disease Ontology : 12 A sleep apnea that is characterized by repeated collapse and obstruction of the upper airway during sleep, which results in reduced airflow (hypopnea) or complete airflow cessation (apnea), oxygen desaturation, and arousals from sleep.

Genetics Home Reference : 26 Obstructive sleep apnea is a condition in which individuals experience pauses in breathing (apnea) during sleep, which are associated with partial or complete closure of the throat (upper airway). Complete closure can lead to apnea while partial closure allows breathing but decrease the intake of oxygen (hypopnea).

OMIM : 58 Obstructive sleep apnea is a common, chronic, complex disease associated with serious cardiovascular and neuropsychologic sequelae and with substantial social and economic costs (Palmer et al., 2003). (107650)

Wikipedia : 77 Obstructive sleep apnea (OSA) is the most common type of sleep apnea and is caused by complete or... more...

Sources

Related Diseases for Apnea, Obstructive Sleep

About this section

Diseases related to Apnea, Obstructive Sleep via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 575)
# Related Disease Score Top Affiliating Genes
1 kawasaki disease 32.1 CRP IL6 TNF
2 gestational diabetes 30.8 ADIPOQ INS LEP
3 glucose intolerance 30.6 ADIPOQ CRP INS LEP
4 end stage renal failure 30.6 CRP IL6 LEP TNF
5 aortic disease 30.5 CRP IL6 REN
6 periodontitis 30.5 CRP IL6 TNF
7 obesity-hypoventilation syndrome 30.5 ADIPOQ IL6 LEP
8 critical limb ischemia 30.5 IL6 TNF
9 fatty liver disease, nonalcoholic 1 30.4 ADIPOQ INS LEP
10 nonalcoholic steatohepatitis 30.4 ADIPOQ INS LEP TNF
11 pericardial effusion 30.4 CRP IL6 REN
12 intermittent claudication 30.3 CRP HTR2A IL6
13 bacterial meningitis 30.3 CRP IL6 TNF
14 meningitis 30.3 CRP IL6 TNF
15 interstitial lung disease 30.3 EDN1 IL6 TNF
16 peripheral nervous system disease 30.3 IL6 INS TNF
17 chronic fatigue syndrome 30.3 HTR2A IL6 TNF
18 periodontal disease 30.3 CRP IL6 TNF
19 systolic heart failure 30.2 CRP EDN1 IL6
20 prader-willi syndrome 30.2 ADIPOQ HCRT INS LEP
21 mixed sleep apnea 30.2 AHI1 MMD
22 cystitis 30.2 CRP IL6 TNF
23 arteriosclerosis 30.2 ADIPOQ CRP EDN1 IL6 INS
24 idiopathic edema 30.2 ADIPOQ EDN1 INS
25 juvenile rheumatoid arthritis 30.2 CRP IL6 TNF
26 bronchiolitis 30.2 CRP IL6 TNF
27 purpura 30.2 CRP IL6 TNF
28 sleep apnea 30.2 ADIPOQ CRP EDN1 HCRT HTR2A IL6
29 angina pectoris 30.2 CRP EDN1 IL6
30 coronary heart disease 1 30.2 ADIPOQ CRP IL6 INS
31 nonalcoholic fatty liver disease 30.2 ADIPOQ INS LEP
32 ischemic heart disease 30.1 CRP IL6 TNF
33 major depressive disorder 30.1 HCRT HTR2A IL6 TNF
34 complex regional pain syndrome 30.1 EDN1 IL6 TNF
35 narcolepsy 30.1 HCRT LEP TNF
36 pre-eclampsia 30.1 ADIPOQ EDN1 IL6 LEP REN
37 disease of mental health 30.1 HCRT HTR2A IL6
38 eclampsia 30.0 EDN1 REN TNF
39 lipid metabolism disorder 30.0 ADIPOQ CRP INS LEP
40 liver disease 30.0 ADIPOQ IL6 INS LEP TNF
41 respiratory failure 30.0 CRP SLC4A1 TNF
42 vascular disease 29.9 ADIPOQ CRP EDN1 IL6 INS REN
43 body mass index quantitative trait locus 11 29.9 ADIPOQ CRP HCRT IL6 INS LEP
44 pulmonary edema 29.9 CRP EDN1 REN TNF
45 periodic limb movement disorder 29.8 CTNNBL1 FXYD1 HTR2A
46 fatty liver disease 29.8 ADIPOQ IL6 INS LEP TNF
47 kidney disease 29.7 ADIPOQ CRP EDN1 IL6 INS REN
48 atherosclerosis susceptibility 29.7 ADIPOQ CRP IL6 INS TNF
49 diabetes mellitus 29.7 ADIPOQ CRP EDN1 IL6 INS LEP
50 cerebrovascular disease 29.6 ADIPOQ CRP IL6 INS REN TNF

Graphical network of the top 20 diseases related to Apnea, Obstructive Sleep:



Diseases related to Apnea, Obstructive Sleep
Sources

Symptoms & Phenotypes for Apnea, Obstructive Sleep

About this section

Human phenotypes related to Apnea, Obstructive Sleep:

33
# Description HPO Frequency HPO Source Accession
1 focal impaired awareness seizure 33 HP:0002384
2 obstructive sleep apnea 33 HP:0002870
3 anosmia 33 HP:0000458
4 excessive daytime somnolence 33 HP:0001262
5 snoring 33 HP:0025267

Symptoms via clinical synopsis from OMIM:

58
Resp:
obstructive sleep apnea
snoring

Misc:
hypersomnolence
restless movements during sleep

Neuro:
anosmia
partial complex seizures

Clinical features from OMIM:

107650

UMLS symptoms related to Apnea, Obstructive Sleep:


seizures, tremor, dyspnea, back pain, apnea, pain, headache, syncope, excessive daytime somnolence, snoring, chronic pain, sciatica, wheezing, sleep disturbances, cheyne-stokes respiration, coughing, vertigo/dizziness, sleeplessness, labored breathing, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified

MGI Mouse Phenotypes related to Apnea, Obstructive Sleep:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.15 ADIPOQ CENPJ CRP EDN1 FXYD1 HCRT
2 behavior/neurological MP:0005386 10.1 ADIPOQ AHI1 CENPJ HCRT HTR2A IL6
3 growth/size/body region MP:0005378 10.06 ADIPOQ AHI1 CENPJ EDN1 HCRT IL6
4 homeostasis/metabolism MP:0005376 10.03 ADIPOQ AHI1 CENPJ CRP EDN1 HCRT
5 adipose tissue MP:0005375 9.91 ADIPOQ CENPJ IL6 INS LEP TNF
6 immune system MP:0005387 9.9 ADIPOQ AHI1 CENPJ CRP CTNNBL1 IL6
7 muscle MP:0005369 9.73 ADIPOQ CENPJ EDN1 FXYD1 HCRT HTR2A
8 renal/urinary system MP:0005367 9.23 ADIPOQ AHI1 EDN1 IL6 INS LEP
Sources

Drugs & Therapeutics for Apnea, Obstructive Sleep

About this section

PubMedHealth treatment related to Apnea, Obstructive Sleep: 64

If you are very overweight, losing weight can help improve sleep apnea. There are also many treatment options that aim to relieve sleep apnea. These include machines that support breathing during the night, surgery, and special aids such as mouth guards. Some of these treatments have been scientifically proven to help people with sleep apnea. Medication is currently not used for the treatment of sleep apnea. There is no scientific evidence that the available medications work.The most effective treatment for severe sleep apnea is called CPAP therapy. CPAP stands for “continuous positive airway pressure.” In this treatment approach, air is taken from the immediate surroundings and blown into your airways at night using low pressure. While you sleep, you wear a breathing mask that is connected to a machine called a respirator. The pressure keeps the upper airways open. People who use this machine have fewer breathing pauses, or even none at all. This can noticeably improve the symptoms such as tiredness during the day. Common side effects include a dry throat and an irritated, sometimes blocked nose.

Drugs for Apnea, Obstructive Sleep (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 449)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
2
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
3
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
4
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
5
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
6
Donepezil Approved Phase 4 120014-06-4 3152
7
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
8
mometasone furoate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 83919-23-7
9
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 2078-54-8 4943
10
Acetaminophen Approved Phase 4,Phase 3,Not Applicable 103-90-2 1983
11
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113775-47-6 5311068 68602
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 437-38-7 3345
13
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
14
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Not Applicable 68-04-2
15
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
16
Xylometazoline Approved, Investigational Phase 4,Not Applicable 526-36-3 5709
17
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
18
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
19
Nitric Oxide Approved Phase 4 10102-43-9 145068
20
Ibuprofen Approved Phase 4,Phase 3,Not Applicable 15687-27-1 3672
21
Ethanol Approved Phase 4,Phase 3,Not Applicable 64-17-5 702
22
Norepinephrine Approved Phase 4,Not Applicable 51-41-2 439260
23
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6740-88-1 3821
24
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
25
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
26
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
27
Promethazine Approved, Investigational Phase 4,Phase 1 60-87-7 4927
28
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68693-11-8 4236
29
Sodium oxybate Approved Phase 4 502-85-2 5360545
30
Diphenhydramine Approved, Investigational Phase 4,Phase 1 147-24-0, 58-73-1 3100
31
Zolpidem Approved Phase 4 82626-48-0 5732
32
Budesonide Approved Phase 4,Phase 3,Phase 1 51333-22-3 5281004 63006
33
Acetazolamide Approved, Vet_approved Phase 4,Phase 2,Not Applicable 59-66-5 1986
34
Carbidopa Approved Phase 4 28860-95-9 34359
35
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
36
Levodopa Approved Phase 4 59-92-7 6047
37
Fluticasone Approved, Experimental Phase 4,Phase 3,Not Applicable 90566-53-3 62924
38
Ondansetron Approved Phase 4,Phase 3 99614-02-5 4595
39
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 1177-87-3
41
Nitrous oxide Approved, Vet_approved Phase 4,Not Applicable 10024-97-2 948
42
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 50-02-2 5743
43
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Not Applicable 28523-86-6 5206
44
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
45
Mannitol Approved, Investigational Phase 4,Phase 3 69-65-8 6251 453
46
Adalimumab Approved Phase 4 331731-18-1 16219006
47
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
48
Angiotensin II Approved, Investigational Phase 4,Phase 2,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
49
Desflurane Approved Phase 4 57041-67-5 42113
50
Remifentanil Approved Phase 4,Early Phase 1 132875-61-7 60815

Interventional clinical trials:

(show top 50) (show all 1560)
# Name Status NCT ID Phase Drugs
1 Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01590420 Phase 4
2 Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients Unknown status NCT01524510 Phase 4
3 PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
4 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
5 Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic Unknown status NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
6 Comparison of the Pentax AWS® With the Macintosh Laryngoscopic Intubation in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01428570 Phase 4
7 CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients. Unknown status NCT01771406 Phase 4 Nebivolol
8 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea. Unknown status NCT02963597 Phase 4
9 Somnodent vs Herbst in Mild and Moderate OSA Patients Unknown status NCT02724865 Phase 4
10 Donepezil Treatment for Sleep Apnea Patients Unknown status NCT00912457 Phase 4 donepezil;placebo
11 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
12 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
13 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study Unknown status NCT01796769 Phase 4
14 Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study Unknown status NCT01505959 Phase 4
15 Effects of Botulinum Toxin Type A(Meditoxin®) on Sleep Bruxism Unknown status NCT01336439 Phase 4 Botulinum toxin type A (Meditoxin®)
16 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome Completed NCT01635010 Phase 4
17 The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea Active, not recruiting NCT02714400 Phase 4 Venlafaxine;Placebo
18 FAST as a Treatment for Obstructive Sleep Apnea Terminated NCT01611779 Phase 4
19 Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy Completed NCT02425202 Phase 4 Ketamine
20 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
21 Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children Terminated NCT01027806 Phase 4 Montelukast
22 Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
23 Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea Completed NCT02494102 Phase 4 Modafinil;Placebo
24 Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea Completed NCT00307957 Phase 4
25 Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients Completed NCT00741520 Phase 4
26 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
27 Burden of Obstructive Sleep Apnea in Stroke (BOSAST) Terminated NCT00952211 Phase 4
28 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
29 The Impact of Arousal Threshold in Obstructive Sleep Apnea Completed NCT02264353 Phase 4 Donepezil;placebo
30 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
31 Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease Recruiting NCT03111485 Phase 4 Sinemet CR;Placebo oral capsule
32 Obstructive Sleep Apnea Treatment on Cardiovascular Events in Patients With Acute Cardiogenic Pulmonary Edema: CPAP-CARE STUDY. Recruiting NCT03936751 Phase 4
33 Early Signs of Atherosclerosis in Obstructive Sleep Apnea: Effects of Treatment Completed NCT00400543 Phase 4
34 Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea Withdrawn NCT01861145 Phase 4 Nasonex
35 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
36 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate
37 Efficacy of CPAP Treatment on Blood Pressure of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome Completed NCT01508754 Phase 4
38 Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome Recruiting NCT02295202 Phase 4
39 Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea Terminated NCT00730041 Phase 4
40 Vasoactive Hormones During the Night in Patients With Obstructive Sleep Apnea Before and After Treatment With CPAP. Completed NCT00360659 Phase 4
41 Effect of Ketorolac on Post Adenotonsillectomy Pain Recruiting NCT03467750 Phase 4 Ketorolac;Standard of Care
42 Serotonin and the Upper Airway in Obstructive Sleep Apnea Completed NCT00100464 Phase 4 Paroxetine;5HTP
43 Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients Completed NCT00729963 Phase 4 Sibutramine
44 Outcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA Withdrawn NCT02056678 Phase 4 acetaminophen, IV preparation
45 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
46 Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea Completed NCT01344759 Phase 4 Dexmedetomidine;Propofol
47 Nasal Decongestion and Obstructive Sleep Apnea Completed NCT00630474 Phase 4 xylometazoline
48 Effects of Continuous Positive Airway Pressure (CPAP) in Heart Remodeling by Magnetic Resonance Imaging (MRI) Terminated NCT00727454 Phase 4
49 Effects of Continuous Positive Airway Pressure and Valsartan Treatments on Arterial Blood Pressure in OSAS Patients Completed NCT00409487 Phase 4 Valsartant treatment
50 Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome Completed NCT02717780 Phase 4 Fentanyl and sevoflurane;Remifentanil and desflurane

Search NIH Clinical Center for Apnea, Obstructive Sleep

Cochrane evidence based reviews: sleep apnea, obstructive

Sources

Genetic Tests for Apnea, Obstructive Sleep

About this section

Genetic tests related to Apnea, Obstructive Sleep:

# Genetic test Affiliating Genes
1 Obstructive Sleep Apnea Syndrome 30
Sources

Anatomical Context for Apnea, Obstructive Sleep

About this section

MalaCards organs/tissues related to Apnea, Obstructive Sleep:

42
Heart, Testes, Endothelial, Liver, Tongue, Brain, Kidney
Sources

Publications for Apnea, Obstructive Sleep

About this section

Articles related to Apnea, Obstructive Sleep:

(show top 50) (show all 2030)
# Title Authors Year
1
Risk of Obstructive Sleep Apnea Syndrome in Psoriasis Patients. ( 31029070 )
2019
2
Different VDR, VDBP genotypes and vitamin D levels may effect obstructive sleep apnea syndrome. ( 30782293 )
2019
3
Inflammatory cytokines tumor necrosis factor-α, interleukin-8 and sleep monitoring in patients with obstructive sleep apnea syndrome. ( 30783447 )
2019
4
Sleep-related painful erection in a patient with obstructive sleep apnea syndrome. ( 30631143 )
2019
5
Arousal index as a marker of carotid artery atherosclerosis in patients with obstructive sleep apnea syndrome. ( 29779142 )
2019
6
Therapeutic Efficacy of Twin-Block and Fixed Oral Appliances in Patients with Obstructive Sleep Apnea Syndrome. ( 28422345 )
2019
7
The relation between retrobulbar blood flow and posterior ocular changes measured using spectral-domain optical coherence tomography in patients with obstructive sleep apnea syndrome. ( 29594838 )
2019
8
Proteomic biomarkers of cognitive impairment in obstructive sleep apnea syndrome. ( 29968150 )
2019
9
The impact of obesity in cognitive and memory dysfunction in obstructive sleep apnea syndrome. ( 29955085 )
2019
10
Serum levels of NGAL and cystatin C as markers of early kidney dysfunction in patients with obstructive sleep apnea syndrome. ( 29946947 )
2019
11
Obstructive sleep apnea syndrome and olfactory perception: An OERP study. ( 30006255 )
2019
12
Efficacy of Upper Gastrointestinal Endoscopic Examination to Identify Patients with Obstructive Sleep Apnea Syndrome: A Retrospective Cross-Sectional Study. ( 30179870 )
2019
13
Auditory Deficits in Patients With Mild and Moderate Obstructive Sleep Apnea Syndrome: A Speech Syllable Evoked Auditory Brainstem Response Study. ( 30134647 )
2019
14
The effect of physical strain on breeders patients with obstructive sleep apnea syndrome. ( 30472194 )
2019
15
Association Between 25-Hydroxyvitamin D and Bone Mineral Density in People With Obstructive Sleep Apnea Syndrome. ( 30396726 )
2019
16
P-wave dispersion as a simple tool for screening childhood obstructive sleep apnea syndrome. ( 30580188 )
2019
17
Internal nasal dilator in patients with obstructive sleep apnea syndrome and treated with continuous positive airway pressure. ( 30715034 )
2019
18
The role of the nasal valve in patients with obstructive sleep apnea syndrome. ( 30715032 )
2019
19
Application of machine learning to predict obstructive sleep apnea syndrome severity. ( 30696334 )
2019
20
A novel intermittent negative air pressure device ameliorates obstructive sleep apnea syndrome in adults. ( 30690676 )
2019
21
Rapid Maxillary Expansion and Adenotonsillectomy in 9-Year-Old Twins With Pediatric Obstructive Sleep Apnea Syndrome: An Interdisciplinary Effort. ( 30688350 )
2019
22
The use of cardiopulmonary exercise testing in identifying the presence of obstructive sleep apnea syndrome in patients with compatible symptomatology. ( 30684645 )
2019
23
In response to "Obstructive sleep apnea syndrome should always be screened in patients complaining of nocturia". World J Urol. 2018. ( 30656495 )
2019
24
Histological, Ultrastructural, and Physiological Evaluation of a Rat Model of Obstructive Sleep Apnea Syndrome. ( 30851162 )
2019
25
The association between obstructive sleep apnea syndrome and metabolic syndrome: a confirmatory factor analysis. ( 30820851 )
2019
26
Reflections on the article "Correlation of lung function and respiratory muscle strength with functional exercise capacity in obese individuals with obstructive sleep apnea syndrome"Authors' replyCorrelation of lung function and respiratory muscle strength with functional exercise capacity in obese individuals with obstructive sleep apnea syndromeIs BMI the best measure of obesityThe relationship between physical functional capacity and lung function in obese children and adolescents. ( 31038650 )
2019
27
Plasma α-synuclein levels are increased in patients with obstructive sleep apnea syndrome. ( 31020003 )
2019
28
Posterior segment assessment in patients with obstructive sleep apnea syndrome. ( 30949928 )
2019
29
Author Correction: A randomized controlled trial of an ambulatory approach versus the hospital-based approach in managing suspected obstructive sleep apnea syndrome. ( 30940824 )
2019
30
Effect of positive airway pressure therapy in children with obstructive sleep apnea syndrome: does positive airway pressure use reduce pedestrian injury risk? ( 30928116 )
2019
31
Editorial - Obstructive sleep apnea syndrome and recurrent upper airway disease in children. ( 30920640 )
2019
32
Obstructive sleep apnea syndrome in the pediatric age: the role of the anesthesiologist. ( 30920637 )
2019
33
Obstructive sleep apnea syndrome in the pediatric age: the role of the dentist. ( 30920636 )
2019
34
Obstructive sleep apnea syndrome in the pediatric age: the role of the otorhinolaryngologist. ( 30920635 )
2019
35
Obstructive sleep apnea syndrome in the pediatric age: the role of the pneumologist. ( 30920630 )
2019
36
Evolution of obstructive sleep apnea syndrome, nasal flow and systolic pressure of the pulmonary artery in children with indication for adenoidectomy and/or tonsillectomy over 18 months. ( 30897517 )
2019
37
The severity of obstructive sleep apnea syndrome cannot predict the accumulation of brain amyloid by imaging with [11C]-Pittsburgh compound B PET computed tomography in patients with a normal cognitive function. ( 30887231 )
2019
38
Effects of a Combined Community Exercise Program in Obstructive Sleep Apnea Syndrome: A Randomized Clinical Trial. ( 30875753 )
2019
39
Mandibular advancement reveals long-term suppression of breathing discomfort in patients with obstructive sleep apnea syndrome. ( 30872167 )
2019
40
Lower urinary tract symptoms and obstructive sleep apnea syndrome: Urodynamic evolution before and after one year of treatment with continuous positive airway pressure. ( 31103396 )
2019
41
ANNALS EXPRESS: Correlation of serum meteorin-Like concentration with the presence and severity of obstructive sleep apnea syndrome. ( 31088112 )
2019
42
Executive Function Impairments in Adolescents With Obesity and Obstructive Sleep Apnea Syndrome. ( 31046409 )
2019
43
Evaluation of quality of life, anxiety, and depression in the spouses of patients with obstructive sleep apnea syndrome. ( 30975956 )
2019
44
Non-alcoholic fatty liver disease is an independent risk factor for inflammation in obstructive sleep apnea syndrome in obese Asian Indians. ( 30032465 )
2019
45
Effect of Continuous Positive Airway Pressure on Overactive Bladder Symptoms in Patients with Obstructive Sleep Apnea Syndrome. ( 30319868 )
2018
46
Risk of Alzheimer's Disease in Obstructive Sleep Apnea Syndrome: Amyloid-β and Tau Imaging. ( 30320587 )
2018
47
Perinatal risk factors for obstructive sleep apnea syndrome in children. ( 30321822 )
2018
48
Effects of 12 weeks of regular aerobic exercises on autonomic nervous system in obstructive sleep apnea syndrome patients. ( 30328014 )
2018
49
The triad of obstructive sleep apnea syndrome, COPD, and obesity: sensitivity of sleep scales and respiratory questionnaires. ( 30043886 )
2018
50
Brief Review: Ergospirometry in Patients with Obstructive Sleep Apnea Syndrome. ( 30065219 )
2018
Sources

Variations for Apnea, Obstructive Sleep

About this section

ClinVar genetic disease variations for Apnea, Obstructive Sleep:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 RYR1 NM_000540.2(RYR1): c.10097G> T (p.Arg3366Leu) single nucleotide variant Uncertain significance GRCh38 Chromosome 19, 38519292: 38519292
2 RYR1 NM_000540.2(RYR1): c.10097G> T (p.Arg3366Leu) single nucleotide variant Uncertain significance GRCh37 Chromosome 19, 39009932: 39009932
3 SYNE2 NM_182914.2(SYNE2): c.19624G> T (p.Gly6542Trp) single nucleotide variant Uncertain significance GRCh38 Chromosome 14, 64218479: 64218479
4 SYNE2 NM_182914.2(SYNE2): c.19624G> T (p.Gly6542Trp) single nucleotide variant Uncertain significance GRCh37 Chromosome 14, 64685197: 64685197
Sources

Expression for Apnea, Obstructive Sleep

About this section
Search GEO for disease gene expression data for Apnea, Obstructive Sleep.
Sources

Pathways for Apnea, Obstructive Sleep

About this section

Pathways related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 66
Show member pathways
 12.53 ADIPOQ IL6 INS LEP TNF
2
Selenium Micronutrient Network 1
Show member pathways
 12.04 CRP IL6 INS TNF
3
HIF-1 signaling pathway 38
11.69 EDN1 IL6 INS
4
AGE-RAGE signaling pathway in diabetic complications 38
11.67 EDN1 IL6 TNF
5
Type II diabetes mellitus 1 38
Show member pathways
 11.64 ADIPOQ INS TNF
6
Adipogenesis 1
11.47 ADIPOQ IL6 INS LEP TNF
7
Adipocytokine signaling pathway 38
11.45 ADIPOQ LEP TNF
8
Lung fibrosis 1
11.34 EDN1 IL6 TNF
9
Legionellosis 38
11.24 HSPA1A IL6 TNF
10
Development_Leptin signaling via JAK/STAT and MAPK cascades 23
Show member pathways
 10.91 CRP EDN1 LEP
11
Overview of nanoparticle effects 1
10.61 CRP IL6 TNF
12
Transcription factor regulation in adipogenesis 1
10.27 ADIPOQ IL6 LEP TNF
Sources

GO Terms for Apnea, Obstructive Sleep

About this section

Cellular components related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 ADIPOQ CRP EDN1 IL6 INS LEP
2 extracellular region GO:0005576 9.36 ADIPOQ CRP EDN1 HCRT HSPA1A IL6

Biological processes related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.91 CRP HSPA1A IL6 INS TNF
2 defense response to Gram-positive bacterium GO:0050830 9.81 CRP IL6 TNF
3 positive regulation of cold-induced thermogenesis GO:0120162 9.8 ADIPOQ HCRT LEP
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 ADIPOQ HTR2A IL6
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.74 INS LEP TNF
6 response to glucocorticoid GO:0051384 9.73 ADIPOQ IL6 TNF
7 cellular response to drug GO:0035690 9.72 ADIPOQ EDN1 REN
8 regulation of blood pressure GO:0008217 9.71 EDN1 LEP REN
9 positive regulation of MAP kinase activity GO:0043406 9.7 EDN1 HTR2A TNF
10 positive regulation of protein kinase activity GO:0045860 9.67 ADIPOQ MMD TNF
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.67 HSPA1A IL6 INS TNF
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.65 EDN1 IL6 TNF
13 negative regulation of gluconeogenesis GO:0045721 9.64 ADIPOQ INS
14 negative regulation of glucose import GO:0046325 9.64 LEP TNF
15 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.62 ADIPOQ CRP
16 regulation of protein secretion GO:0050708 9.61 INS TNF
17 negative regulation of fat cell differentiation GO:0045599 9.61 ADIPOQ IL6 TNF
18 negative regulation of hormone secretion GO:0046888 9.6 ADIPOQ EDN1
19 artery smooth muscle contraction GO:0014824 9.59 EDN1 HTR2A
20 negative regulation of blood vessel diameter GO:0097756 9.58 CRP INS
21 negative regulation of potassium ion transport GO:0043267 9.58 HCRT HTR2A
22 response to activity GO:0014823 9.58 ADIPOQ EDN1 LEP
23 acute-phase response GO:0006953 9.5 CRP IL6 INS
24 regulation of signaling receptor activity GO:0010469 9.5 ADIPOQ EDN1 HCRT IL6 INS LEP
25 positive regulation of neuroinflammatory response GO:0150078 9.46 IL6 TNF
26 glucose metabolic process GO:0006006 9.46 ADIPOQ INS LEP TNF
27 positive regulation of interleukin-8 production GO:0032757 9.43 ADIPOQ HSPA1A TNF
28 negative regulation of lipid storage GO:0010888 8.92 CRP IL6 LEP TNF
29 positive regulation of cell proliferation GO:0008284 10.02 EDN1 HTR2A IL6 INS LEP

Molecular functions related to Apnea, Obstructive Sleep according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.46 ADIPOQ EDN1 IL6 TNF
2 signaling receptor binding GO:0005102 9.35 ADIPOQ EDN1 HSPA1A LEP REN
3 insulin-like growth factor receptor binding GO:0005159 9.26 INS REN
4 hormone activity GO:0005179 8.92 ADIPOQ EDN1 INS LEP
Sources

Sources for Apnea, Obstructive Sleep

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....